Nguyen T, El Salibi E, Rouleau J L
Department of Medicine and Research Center, Montreal Heart Institute, Montreal, Quebec, Canada.
Circulation. 1998 Nov 10;98(19):2074-80. doi: 10.1161/01.cir.98.19.2074.
Hypertensive patients with left ventricular hypertrophy (LVH) have been found to have greater peri-infarction and postinfarction mortality. In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics.
An acute myocardial infarction (MI) was produced by ligation of the left anterior descending coronary artery. Rats were randomized to either control (n=50), hydralazine (n=41), or ramipril (n=45). Treatments were started 4 hours after infarction and continued for 8 weeks. Ramipril and hydralazine reduced arterial pressure similarly. Medications were stopped 72 hours before euthanasia, at which time hemodynamic, programmed electrophysiological stimulation (PES), and morphological studies were performed. Mortality was decreased in ramipril (56%) compared with hydralazine (78%) and control (82%) SHRs (P=0.008). This was accompanied by a decrease in myocardial hypertrophy and fibrosis and a decrease in inducibility of ventricular arrhythmias by PES in the ramipril group regardless of MI size. Treatment with hydralazine had little or no effect on LVH and cardiac fibrosis and did not modify inducibility of ventricular arrhythmias by PES. Ramipril but not hydralazine prevented the increase in LV end-diastolic pressure in rats with large MIs.
In the SHR, the ACE inhibitor ramipril reduces LVH, cardiac fibrosis, and susceptibility to ventricular arrhythmias by PES and improves survival and LV function. Despite a similar decrease in arterial pressure, hydralazine does not have these beneficial effects.
已发现左心室肥厚(LVH)的高血压患者梗死周围及梗死后死亡率更高。在本研究中,我们评估了自发性高血压大鼠(SHR)梗死后的生存率、室性心律失常易感性、LVH程度和心脏纤维化情况,以及血管紧张素转换酶抑制剂雷米普利和直接血管扩张剂肼屈嗪对这些特征的影响。
通过结扎左冠状动脉前降支造成急性心肌梗死(MI)。将大鼠随机分为对照组(n = 50)、肼屈嗪组(n = 41)或雷米普利组(n = 45)。在梗死后4小时开始治疗,并持续8周。雷米普利和肼屈嗪降低动脉压的效果相似。在安乐死72小时前停止用药,此时进行血流动力学、程控电生理刺激(PES)和形态学研究。与肼屈嗪组(78%)和对照组(82%)的SHR相比,雷米普利组的死亡率降低(56%)(P = 0.008)。无论MI大小,雷米普利组均伴有心肌肥厚和纤维化减轻以及PES诱发室性心律失常的可能性降低。肼屈嗪治疗对LVH和心脏纤维化几乎没有影响,也未改变PES诱发室性心律失常可能性。雷米普利而非肼屈嗪可预防大MI大鼠左心室舒张末期压力升高。
在SHR中,血管紧张素转换酶抑制剂雷米普利可减轻LVH、心脏纤维化和PES诱发室性心律失常的易感性,并改善生存率和左心室功能。尽管动脉压下降程度相似,但肼屈嗪没有这些有益作用。